News of Note—CSL’s flu vaccine sales, Inovio and more

non
In this week's news of note, sales of CSL's Flucelvax quadrivalent flu shot were up 43%. (Pixabay)

Here is some other vaccine news of note for the week:

> Sales of CSL’s Flucelvax quadrivalent flu vaccine were up 43% for the six months leading up to December. Brisbane Times article

> Inovio and The Wistar Institute are collaborating on two vaccines against tuberculosis and malaria, with total grants of more than $4.6 million from the Bill & Melinda Gates Foundation and the NIH. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Three crisis management experts analyzed Sanofi Pasteur’s response to the Dengvaxia situation in the Philippines. The Wall Street Journal commentary

> FDA Commissioner Scott Gottlieb, M.D., said his agency is working with the CDC to understand why protection offered by this year’s flu vaccine is less than optimal. Tweet

> To cope with flu vaccine shortage this year, Hong Kong health officials are considering using shots intended for the southern hemisphere. South China Morning Post article